

# Index

---

- abusive practices 136–8
- accessibility of technology, IP protection 57–8
- advanced pharmaceutical industry 76–7
- cooperation with academic institutions 33
  - creation of Special 301 4, 66–7
  - dominance of 77–81
  - global distribution of pharmaceutical capabilities 81–2
  - importance of IPRs 24, 85–93
  - monopolistic competition in brand names 37
  - objection to compulsory licensing in crises 144
  - role in pushing international IP system 4
  - see also* European pharmaceutical industry
- Advisory Committee (EFPIA) 110
- Advisory Committee for Trade Negotiations (ACTN) 4
- African Group, TRIPs agreement 139, 158, 160, 163
- Ager, Brian 187
- agrochemical products
- EU/India dispute over lack of patent protection 176–80
  - special provisions relating to patent applications 144–5
- AIDs medicines, conflict over patented 216–17
- animals, reservations about patents based on 162–5
- anthrax threat, Cipro debate 217–18
- anti-competitive practices, TRIPs lack of efficacy in eliminating 136–8
- anti-monopolistic policies 5
- applied research 17–18
- Argentina, welfare losses and price increases, patent grants 55
- aspirin 39
- Association of the British Pharmaceutical Industry (ABPI) 92, 104–6, 207–8
- AstraZeneca 87, 88, 92
- auctioning, right to invent 21–2
- availability of technology, IP protection 58–9
- Bale, Harvey 179–80
- Bangladesh, TRIPs agreement 157, 160
- basic research 17, 18
- Basle Capital Adequacy Accord 3
- Berne Convention (1886) 131
- ‘best endeavour’ provisions 158–9
- biological processes, reservations about patents for 163
- biopiracy 162
- biotechnology inventions
- legal protection 111
  - see also* life patenting
- ‘blocking’ phenomenon 27
- Bolar exemptions, commercial testing 180–86
- Bolkestein, Fritz 170
- border measures, TRIPs requirement 133
- Botswana, reaction to TRIPs 157, 158
- brand loyalty 37, 38, 91, 92, 102–3
- Brazil
- IPRs and technological development 62
  - use of trade pressures against 67–8
- Brittan, Sir Leon 172
- built-in agenda, TRIPs 134–5
- Business Software Alliance 4
- Cameroon, demands on TRIPs 160
- Canada
- compulsory licences 59
  - demands on TRIPs agreement 160
  - EU dispute over scope of patent protection 180–86
  - pending Bayer Cipro patents 218

- cartels, anti-competitive practices 136–7
- case-study research 11–12
- Celera 163
- chemicals, relevance of trademarks 39
- CibaGeigy 81, 137
- Cipro debate 217–18
- clinical phases, R&D projects 89
- collaboration, regional and national 109–10
- collective action
  - IPRs as incentive for 118, 206–7
  - organizational structure 104, 108
- Colombia
  - price increases, patent grants 55
  - reaction and demands, TRIPs 139, 157, 160
- commercial testing, Bolar exemptions 180–86
- 133 Committee 110, 111, 208
- Community Patent Convention (CPC) 181
- community perspective, on inventions 20, 26
- company-level structure, pharmaceutical MNCs 103–4
- competition
  - brand names 37
  - during introduction of innovative products 89
  - from generic based companies 80
- competitors, trademarks, as entrance barriers for new 38
- compulsory licensing 59, 143–4
- conditionality, on mandatory use of patents 143–4
- consumer groups, lobbying on IPRs 174
- consumption, of pharmaceuticals 82
- contractual licensing 137–8
- Coordinating Body for the Indigenous Organizations of the Amazon Basin (COICA) 162
- corporate IP activities 104
- cost containment legislation, Germany 106
- cost-reducing inventions, patent grants 28–9
- costs
  - implementation of TRIPs 138, 157
  - innovative drugs 80
  - see also* opportunity costs
- Council for TRIPs 134–6
- counterfeiting 36, 58, 133
- data exclusivity 88–90, 102, 147–8
- Department of Legal Affairs (VFA) 106–7
- dependent patents, conditionality on compulsory licensing 143–4
- developed countries
  - international IP system, empirical implications 51–6
  - non-utilized patents 59
  - pharmaceuticals
    - consumption and sales 82
    - innovative potential 82
    - international trade in 82
  - TRIPs agreement
    - bias in favour of 215
    - implementation dates 132
    - use of DSU 133
  - use of trade retaliation 65–9
  - see also individual countries*; strong IP capability
- developing countries
  - international IP system
    - empirical implications 51–6
    - technological access and availability 57–60
  - IP legislation, pressures to change 66–9
  - pharmaceutical industry in 82
  - pharmaceuticals
    - consumption and sales 82
    - international trade 82
  - TRIPs agreement
    - antagonism towards 215
    - demands concerning public health 218–19
    - demands during ministerial 1999 meeting 158–65
    - implementation dates 132
    - patent ‘protection building measures’ 144–5
    - reactions during 1996 and 1998 ministerial meetings 156–8
    - see also individual countries*; weak IP capability
- development, defined 18
- diminishing returns, identical inventions 25
- direct to consumer advertising 92

- discoveries 18
- discretionary problems, rewarding inventors 22, 23
- Dispute Settlement Understanding (DSU) 110, 132–3
- doctors, brand loyalty 38, 91
- Doha ministerial meeting 218
  - public health
    - advanced pharmaceutical industry, IP position 219–20
    - demands concerning 218–19
    - negotiating a ministerial declaration and agreement on 220–22
    - significance of ministerial declaration 222–3
- domestic politics, international financial agreements 3
- downgrading of TRIPs, efforts to prevent 188–90
- Drug Price Competition and Patent Term Restoration Act (1984) 181–2
- drugs, *see also* essential drugs list; generic products; innovative drugs; NCE-based drugs; out-of-patent products; patented drugs; prescription drugs
- Dunkel, Arthur 130
- dynamic analysis, IPRs 62–4
- EC Approach to Trade-related Aspects of Intellectual Property 191–2
- economic growth
  - support for IPRs 171
  - TRIPs agreement as barrier to 160
- economic justification, IPRs 1–2, 203–4, 214
  - patents 16–34
  - trademarks 34–40
- electronic commerce, IP protection 135
- ‘end use’ products 81–2
- enforcement provisions, TRIPs 133
- epistemic community, pharmaceutical MNCs 104
- essential drugs list (WHO), exclusion from patentability 164
- essentially biological processes, reservations about patents for 163
- European Chemical Industry Council (CEPIC) 115–16, 188
- European Commission
  - Green Paper on counterfeiting and piracy 58
  - retaliation against IP-violating countries 68–9
  - role, trade-related IPR policies 110
  - views on
    - intellectual property rights 170–71
    - TRIPs agreement 172–3
- European Federation of Pharmaceutical Industries and Associations (EFPIA) 3, 101, 108–12, 182, 185, 187, 188, 189, 208, 219
- European Generic Medicines Association (EGA) 183
- European Parliament, IP position, Seattle 193
- European pharmaceutical industry 83
  - dominance of 214–15
  - innovative capacity 84–5
  - IP interests
    - enforcement of 215
    - primary 100–3, 207
  - IP organizational structure
    - inter-industry 115–18, 208–9
    - intra-industry 103–15, 207–8
  - IP rights
    - as dominant factor in field of 6
    - importance of 5–6
    - as incentive for collective action 206–7
  - mergers 79
  - production and trade 83–4
  - R&D expenditure 77
  - TRIPs agreement
    - effect on international agenda (1995–99) 6–7
    - pharmaceuticals *see* pharmaceutical IP agenda
- see also* European Federation of Pharmaceutical Industries and Associations
- European Union
  - IP policy making 110–11
  - IP position, Seattle 191–5
  - views on
    - intellectual property rights 170–72
    - TRIPs agreement 172–4
  - see also* European Commission; European Parliament

- examination system, patent grants 32
- exclusive marketing rights 145, 176–80
- exclusive patent rights 101–2, 142
- exclusive trademark rights 36, 146
- exemptions, exclusive patent rights 142
- expenditure
  - pharmaceutical R&D projects 77, 84, 86
  - on promotion of brand names 91
- experience goods 35
- ‘experimental use’ defence 181, 182
- ‘expression of folklore’ 161
- false information, from trademarks 2
- financing, centrally administered reward systems 22–3
- ‘first to file’ system 114, 115
- ‘first to invent’ system 114, 115
- folklore, IP protection 161
- foreign direct investment (FDI) 61–2, 63
- foreign economic policies, political forces 3
- foreign ownership, patents and trademarks 51–2, 53–4
- France
  - foreign ownership, patents and trademarks 51
  - innovative capacity 84
  - pharmaceutical exports 84
  - trade in IP-related products 54
- free-riding 19–20, 36
- GATT TRIPs and the Pharmaceutical Industry 175
- gene patenting *see* life patenting
- General Assembly, INTERPAT 114
- General System of Preferences (GSP), threat of denial 66
- generic products, trademarks 39, 146
- generic-based companies
  - Bolar exemptions, commercial tests 181–6
  - competition from 80
  - effects of data exclusivity on 90
  - strategic alliances with 81
- generic-based units, within pharmaceutical MNCs 80–81
- geographical indications, registration system for 135
- Germany
  - coercion on Switzerland to alter patent law 66
- cost containment legislation 106
- foreign ownership, patents and trademarks 51
- innovative capacity 84
- pharmaceutical exports 84
- support for IPRs 171
- views on TRIPs agreement 173–4
- see also* Verband Forschender Arzneimittelhersteller
- Gilmartin, Raymond V. 101
- Glaxo Wellcome 79, 101, 105, 117
- GlaxoSmithKline 77, 79, 81, 86, 87, 92, 106, 117
- higher prices, brand loyalty 92
- Human Genome Project 163
- human raw data, free use of 163–4
- identical inventions 25
- implementation of TRIPs
  - dates 132
  - EU demands for rapid implementation 175–6
  - obstacles to 138
  - proposal to extend 160
- income, trade in IP-related products 52–4
- India
  - demands on TRIPs agreement 159
  - EU dispute over lack of patent protection 176–80
  - welfare losses and price increases, patent grants 55
- indigenous knowledge 161–2
- industry, importance attached to patents 24, 171
- industry-government interaction scheme 123
- information
  - non-disclosure/non-reliance period 89–90
  - regarding TRIPs implementation 176
  - see also* data exclusivity; product information; undisclosed information
- information disclosure, IP protection 57–60
- Informed Patient Initiative 92
- innovative capacity, European pharmaceutical industry 84–5

- innovative drugs  
 capability for 79–80  
 competition between MNCs  
   introducing 89  
 patents  
   importance during marketing  
     stage 86–8  
   role during pre-marketing stage  
     88–90  
   potential for introducing 82  
 institutional political economy  
   scholarship 103  
 institutions, internationalization of IPRs  
   212–14  
 insurance tools, patents as 88–90  
 intellectual property, transactions,  
   royalties and licence fees 55  
 Intellectual Property Committee (ABPI)  
   105  
 Intellectual Property Committee (US) 4,  
   68, 117–18, 175, 188–9  
 intellectual property legislation  
   antitrust lawsuits 5  
   inventors' need for 19  
   use of trade retaliation 66–9  
 Intellectual Property Policy Committee  
   – PPC (EFPIA) 208  
 intellectual property protection  
   biotechnology inventions 111  
   electronic commerce 135  
   EU views on 170–72  
   global commitment to 1, 131–2  
   identification of countries with  
     inadequate 66  
   plant breeders 141  
   technological access and availability  
     57–60  
   traditional knowledge 161–2  
   *see also* patent protection; stronger IP  
     protection; trademark protection  
 intellectual property rights  
   advanced pharmaceutical industry  
     as dominant factor in field of 6  
     importance of 5–6  
     as incentive for collective action  
       118, 206–7  
   economic analysis of 7–8  
   inadequate economic justification for  
     1–2, 203–4, 214  
   politically constituted term 4–5  
     Meir Perez Puigade-retaliation 64–70  
     trade retaliation 64–70  
     *see also* exclusive marketing rights;  
       international IP system; patents;  
       trademarks; TRIPs agreement  
 inter-governmental agencies, progress in  
   technical assistance 139–40  
 inter-industry IP organisational structure,  
   pharmaceutical MNCs 115–18  
 interest groups  
   international systemic outcomes 210–  
     12  
   internationalization of IPRs, and need  
     for IPE-based approach 2–5,  
     206–14  
   use of trade retaliation 65–9  
   *see also* individual associations  
 Internal Market Working Party (EFPIA)  
   110  
 International Convention for the  
   Protection of Industrial Property  
   (1883) 47  
 international economy, effect on political  
   structures and groups 3  
 international exhaustion principle 148–9  
 International Federation of  
   Pharmaceutical Manufacturers  
   Association (IFPMA) 101, 102,  
   112–14, 175, 182, 188, 208  
 international financial agreements,  
   domestic politics 3  
 International Generic Pharmaceutical  
   Alliance (IGPA) 183  
 international inter-industry structure,  
   pharmaceutical MNCs 116–18  
 international intra-industry structure,  
   pharmaceutical MNCs 112–15  
 international IP system 47–72  
   empirical implications 51–6  
   European pharmaceutical industry  
     interest in 100–103  
   interest groups, and need for an IPE-  
     based approach 2–5, 206–14  
   IPE explanation for 214  
   rival economic and political  
     explanations for 204–6  
   role of institutions 212–14  
   technology transfer 56–7  
     direct effects on 57–60  
     indirect effects on 60–4  
   theoretical implications 48–51  
   trade retaliation 64–70  
   *see also* trade retaliation 64–70

- International Plant Medicine Corporation 162
- international political economy
  - framework, need for 2–5, 206–14
- international systemic outcomes
  - interest groups 210–12
  - TRIPs agreement 209–10
- international trade, pharmaceuticals 82
- International Trade Commission (US) 58
- international treaties, in TRIPs
  - agreement 131
- International Undertaking on Plant Genetic Resources 164
- INTERPAT 114–15, 208
- intra-industry IP organizational structure, pharmaceutical MNCs 103–15
- ‘inventing around’ phenomenon 27
- inventions
  - allocation of, as factors of production 27–9
  - biotechnology 111, 135
  - centrally administered reward system 21–3
  - production and distribution in absence of patents 19–21
  - and research 18–19
- inventive activities
  - patents
    - effects on allocation of resources 25–7
    - as incentive for 24–5, 33
    - rhetoric about IPRs’ ability to stimulate 207
- investors, new pharmaceutical products 84
- IPRs *see* intellectual property rights
- Japan
  - foreign ownership of trademarks 51
  - IP position, Seattle 192–3
  - R&D expenditure, pharmaceutical industry 77
- Japanese Federation of Economic Organizations 117–18
- joint decision making, IP trade-related negotiations 208
- joint ventures
  - research and development 33
  - technology transfer 61
- Kenya, reaction and demands, TRIPs 139, 157, 158, 159, 163
- knowledge
  - monopolisation 16
  - see also* epistemic community; scientific knowledge; traditional knowledge
- knowledge-based alliances 79
- Korea, pressure to amend IP legislation 67, 68
- Landfermann, Hans George 171
- Latvia, demands on TRIPs 160
- least developed countries (LDCs)
  - TRIPs agreement
    - antagonism towards 215
    - demands concerning public health 218–19
    - demands during 1999 ministerial meeting 158–65
    - implementation dates 132
    - obstacles in process of implementation 138, 139
    - patent ‘protection building measures’ 144–5
    - reactions during 1996 and 1998 ministerial meetings 156–8
    - technical assistance to 138, 139–40
    - see also* weak IP capability
- licensing agreements 61
- life patenting 135, 141, 163–4, 191
- lobbying, on IPRs 108–12, 174
- Losec 87, 88
- low IP capability *see* weak IP capability
- mailbox applications, TRIPs agreement 144–5
- mailbox procedures, dispute with India over 176–80
- market access, reactions to TRIPs 157
- market bias, inventive activities 26–7
- market exclusivity 1–2, 89–90, 145
- market power, trademarks 37–9
- market value, pharmaceutical MNCs 77
- marketable products, pharmaceutical MNCs 79–80
- marketing stage, importance of patents 86–8
- Médecins Sans Frontières (MSF) 189,

- medicines
  - access to, and patented drugs dispute, Doha 218–23
  - appropriation of traditionally owned 162
  - dispute over local production of patented 216–17
- Medicines and Related Substances Control Amendment Act 216
- Merck 77, 80, 86, 88, 92, 101, 106
- mergers and acquisitions 78–9, 88
- micro-organisms, reservations about patents for 163
- microbiological processes, reservations about patents for 163
- minimum protection standards 131
- misallocated resources
  - secret inventions 20–21
  - through reproducing inventions 26
- monopolistic competition, brand names 37
- monopolistic effects, IPRs, downplaying of 101, 207
- monopolistic industries, market bias, inventive activities 25
- monopolized trading environments 48, 49
- morality, denial of patentability 141
- Morocco, demands on TRIPs 160
- most-favoured-nation (MFN) treatment 131
- multinational companies
  - foreign economic policies 3
  - see also* advanced pharmaceutical industry
- national emergencies, compulsory licensing 144
- national income, international IP system 49
- national level structure, pharmaceutical MNCs 104–7, 119
- national share, patents and trademarks 51–2, 53–4
- national treatment, principle of 47, 65, 131
- NCE-based drugs 81, 84, 85
- New Trade Policy Instruments 68
- non-disclosure/non-reliance period 89–90
- non-discrimination principle 141
- non-governmental organizations
  - accusations about restricted access to medicines 189
  - increased anti-patent activities 217
  - opposition to life patenting 191
  - TRIPs agreement, demands concerning public health 218–19
- non-utilized patents 59
- non-violation disputes 135
  - TRIPs agreement, demands on 159–60
- north-south divide
  - international IP system 4, 48, 49
  - TRIPs negotiations 129, 209
- notifications system, TRIPs 134
- Novartis 77, 79, 81, 137
- oligopolistic industries, market bias, inventive activities 25
- Omnibus Trade and Competitiveness Act (1988) 4, 66–7
- opportunity costs, secret inventions 20
- organizational structure, pharmaceutical industry 103–18, 122, 215
- origin, trademarks as indicators of 35
- out-of-patent products
  - competition from generic-based companies 80
  - prices 86–7
  - trademarks, preventing decline in market share 91
- over-inventing, patents as a cause of 25
- over-investment, inventive activities 24–5
- over-the-counter drugs (OTCs) 92, 93
- overpricing, patented products 55, 56
- ownership, marks designating 35
- Pakistan
  - demands on TRIPs 160, 162
  - dispute over mailbox procedures and EMRs 180
  - ‘paradox of patents’ 23
- Paraguay, reaction to TRIPs 157
- parallel imports, global policy 148–9
- Paris Convention (1883) 131, 146, 147
- patent attorneys 104
- patent concentration 32–4
- patent expires, profit flow 86–8

- patent grants
  - establishing criteria for 31–2
  - priority conflicts 114
  - reservations about those based on
    - plants and animals 162–5
  - subject matter 141–2
  - TRIPs agreement 17
  - welfare losses and price increases 54–6
- patent pooling agreements 33
- patent protection
  - applications for, at pre-clinical stage 89
  - EU views on 171
  - European pharmaceutical industry
    - dispute with Canada over scope of 180–86
    - dispute with India over lack of 176–80
    - interest in 101–2
  - extension of 111
  - incentive for inventive activities 24–5
  - pharmaceutical products and processes 141
  - profit flows 86–7
  - ‘protection building measures’ 144–5
  - TRABD views on 117
  - use of trade pressures regarding 67
  - see also* patent term of protection; Supplementary Protection Certificate
- patent system 23–4
  - external pressures on Switzerland to adopt 65–6
  - inventions, allocation of, as factors of production 27–9
  - inventive activities
    - effects on allocation of resources 25–7
    - as incentive for 24–5
  - patent concentration 32–4
  - patentability criteria 31–2
  - structural trade-off 2
- patent term of protection 29–31
  - increase in 142–3
  - MNCs’ influence on doctors 91
- patentability *see* patent grants
- patented drugs
  - and access to medicines dispute 218–23
  - price increases 55–6
  - welfare losses 54–5
- patentees
  - anti-competitive practices 136–7
  - rights 17
- patents 16–34
  - alternative reward system for 21–3
  - exclusive rights 142
  - foreign and national share 51, 53–4
  - importance during marketing stage 86–8
  - inadequate economic justification for 1–2
  - inventions, production and distribution in absence of 19–21
  - market exclusivity 1–2
  - non-utilized 59
  - research, development and inventions 17–19
  - role during pre-marketing stage 88–90
  - technological access and availability 57
  - TRIPs pharmaceutical agenda 141–5
- peer-group examination 134
- personnel, pharmaceutical MNCs 104
- Pfizer 4, 77, 86, 92, 117, 189
- pharmaceutical capabilities, global distribution of 81–2
- pharmaceutical industry *see* advanced pharmaceutical industry
- Pharmaceutical Industry Competitiveness Task Force 105
- pharmaceutical IP agenda, TRIPs 140–49
  - conflicts concerning 215
    - patented AIDS medicines in South Africa 216–17
  - patents, CIPRO and anthrax 217–18
- developing countries and LDCs 156–66
  - demands during 1999 ministerial meeting 158–65
  - reactions during ministerial meetings (1996 and 1998) 156–8
- European pharmaceutical industry
  - demands for rapid implementation 175–6
  - dispute with Canada over scope of patent protection 180–86

- dispute with India over lack of patent protection 176–80
- efforts for exploiting and preserving 187–95, 215
- interest groups and international systemic outcomes 210–12
- international exhaustion principle 148–9
- patents 141–5
- public health
  - demands of developing countries and LDCs 218–19
  - IP position of advanced pharmaceutical industry 219–20
  - negotiating a declaration and agreement on 220–22
  - significance of ministerial declaration 222–24
- trademarks 145–7
- undisclosed information 147–8
- Pharmaceutical Manufacturers of America (PMA) 4, 67
- pharmaceutical MNCs *see* advanced pharmaceutical industry
- Pharmaceutical Price Regulation Scheme (PPRS) 105
- pharmaceutical products
  - consumption and sales 82
  - European exports 83–4
  - global sales and patent protection periods 87
  - innovative potential 82
  - international trade 82
  - investors in new, Europe 84
  - relevance of trademarks 39
  - sale of counterfeit 58
  - supplementary protection certificates 111
  - TRIPs agreement *see* pharmaceutical IP agenda
  - use of trade pressures regarding patent protection 66–8
  - world production 77
  - see also* drugs
- pipeline drugs, importance of patents 88–90
- pipeline protection 145
- piracy 36, 58, 133, 162
- plant breeders, IP protection 141
- plants, reservations about patents based on 162–5
- plausibility, in research 11–14
- policy committees (EFPIA) 108–9
- political forces, and foreign economic policy 3
- Pratt, Edmund 4
- pre-clinical stage, R&D projects 89
- pre-emptive patenting 27, 59
- 'pre-expiration testing' 184
- pre-marketing stage, importance of patents 88–90
- preferential treatment, US threat of denial 66
- prescription drugs
  - brand loyalty 91
  - brand marketing 92
  - leading companies in sales of 78
  - reclassification to OTCs 93
  - sales (2001 and 2002) 77
- price calculations, brand loyalty 38
- price increases, and patent grants 54, 55–6
- prices
  - monopolized trading environments 48, 49
  - post-patent generic drugs 86–7
  - see also* higher prices; share prices
- Priority Action Teams (EFPIA) 109, 208
- priority conflicts, patent grants 114
- Priority Foreign Countries 66
- Priority Watch List 66
- product amalgamation, quality reduction 39–40
- product development strategies, patenting 89
- product differentiation 37
- product information 34, 35–7, 38
- profit flows, patent protection 86–7
- profit margins, pharmaceutical MNCs 77, 79
- Promoting Innovation Through Patents 171
- promotional activities, brand loyalty 91, 92
- public health, Doha ministerial meeting
  - advanced pharmaceutical industry IP position 219–20
  - demands of developing countries and LDCs 218–19

- negotiating a declaration and agreement 220–22
- significance of declaration 222–3
- quality, trademarks as indicators of 35, 36
- quality reduction, product amalgamation 39–40
- regional inter-industry structure, pharmaceutical MNCs 115–16
- regional intra-industry structure, pharmaceutical MNCs 108–12
- regional policy making, interest groups 3
- registered trademarks *see* trademarks
- registration system
  - patent grants 32
  - for protecting IPRs of geographical indications 135
- ‘The Relationship Between the Provisions of the TRIPs Agreement and Access to Medicines’ 185
- reproduction of inventions, misallocation of resources 26
- reputable trademarks
  - excessive advertising at the cost of quality 36
  - market power 37–8
- research and development (R&D) 17–18
  - duplication of, patent protection 25
  - joint ventures 33
  - pharmaceutical industry
    - expenditure 77, 84, 86
    - knowledge-based alliances 79
    - projects introducing new drugs 88–9
- research-based companies *see* advanced pharmaceutical industry
- restrictions, licensing agreements 61
- retroactive protection 145
- reward system, for inventions 21–3
- rhetoric, European pharmaceutical industry 101, 207
- right to invent, auctioning 21–2
- Roche Products Inc v. Bolar Pharmaceuticals Co. Inc. 181–6
- Rome Convention (1961) 131
- sales, pharmaceuticals 82
  - innovative drugs 86
  - leading companies 78
  - patent expiry and decline in 87
  - prescription drugs (2001) 77
- scientific knowledge, advances in 18
- Seattle ministerial meeting
  - demands on TRIPs 158–65
  - efforts for preserving TRIPs 187–95
- secret inventions 20, 26, 27–8
- Section 301 (later Special 301) 4, 66–7
- Senegal, demands on TRIPs 160
- Seretide/Advair 86
- share prices, declining 88
- Single Community Trademark policy 102, 111
- Single European Pharmaceutical Market 83
- social burden, trademarks as 39–40
- social desirability
  - IPRs 17, 203
  - reproducing inventions 26
- social progress, creation of inventions 24
- social sciences, plausibility in 11–14
- social utility, trademarks 2
- solidarity, among pharmaceutical MNCs 104
- South Africa, conflict over local production of patented medicines 216–17
- South Korea
  - granting of foreign licences 63
  - use of trade pressures against 67
- Special 301 (formerly Section 301) 66–7
- standardization, international IP system 47–8
- ‘starving inventor’ phenomenon 24
- static analysis, IPRs 62–4
- stockpiling activities 184–5, 186
- strategic alliances 79, 81
- strong IP capability
  - benefits of international IP system 49
  - insufficient assistance to countries with low IP capability 138–40
- stronger IP protection
  - influence on TT calculations 60–64
  - political use of trade retaliation 64–9
- structural trade-off, patent system 2, 40
- subject matter, patentable 141–2
- Supplementary Protection Certificate 111
- Switzerland
  - external pressures to adopt a patent system 65–6

- foreign ownership of patents 51
- innovative capacity 84
- pharmaceutical exports 84
- Sykes, Sir Richard 101
- system of notifications 134
  
- talent migration 50
- Tariff Act of 1930 (US) 66
- technical assistance, to countries with
  - low IP capabilities 138–40, 157, 158
- technical inventions 18–19
- technology transfer
  - international IP system 56–7
    - direct effects 57–60
    - indirect effects 60–64
  - TRIPs agreement
    - demands concerning 158–9
    - requirement to promote 138–9
- Teva Pharmaceuticals 80
- timing of inventions, patent protection 25
- Trade Barriers Regulation 68
- trade in IP-related products
  - international IP system
    - empirical implications 51–6
    - theoretical implications 48–51
- trade liberalization, and IP regulation 173
- trade retaliation 64–9
- trade secrets 90, 102, 147–8
- Trade-related Aspects of Intellectual Property Rights *see* TRIPs agreement
- trademark protection, brand loyalty 102–3
- trademark term of protection 146
- trademarks 34–40
  - European pharmaceutical industry
    - interest in protection of 102–3
  - exclusive rights 36, 146
  - foreign and national share 51–2
  - importance to pharmaceutical MNCs 90–93
  - inadequate economic justification for 1–2
  - licensing agreements 61
  - market power 37–9
  - production and dissemination of
    - product information 35–7
    - as social burden 39–40
    - TRIPs agreement 145–7
  - traditional knowledge, intellectual property protection 161–2
  - Trans Atlantic Business Dialogue (TABD) 117, 175, 188
  - Trans Atlantic Consumer Dialogue (TACD) 174
  - transitional countries, implementation, TRIPs provisions 132
  - Treaty on intellectual property in respect of integrated circuits 131
  - TRIPs agreement 128–52
    - aims 1
    - bias in favour of developed countries 215
    - brief history 128–31
    - built-in flaws 136–40
    - EU views on 172–4
    - European pharmaceutical industry, 1995–99 agenda 6–7
    - international systemic outcomes 209–10
    - lack of harmonization 47
    - major elements 131–6
    - patent grants 17
    - pharmaceuticals *see* pharmaceutical IP agenda
    - UNICE views on 116
    - see also* international IP system
  - TRIPsII, EU demands on possible negotiations 190–91
- UN Convention on Biological Diversity 164
- UNCTAD
  - compulsory licensing 59
  - dominance of IP in developed countries 51–2
  - exclusion rights and exemptions 142
  - influence of price calculations in prescribing 38
  - LDCs 1988 report 139
  - monopolistic competition in brand names 37
  - non-utilized patents 59
  - price differences, pharmaceutical products 92
  - undisclosed information 147–8

- Union of Industrial and Employer's Confederations of Europe (UNICE) 116, 117–18, 175, 182, 187, 189
- United Kingdom
  - foreign ownership, patents and trademarks 51
  - innovative capacity 84
  - pharmaceutical exports 84
  - support for IPRs 171
  - support for TRIPs agreement 173
  - trade in IP-related products 54
- United States
  - dispute over mailbox procedures 180
  - foreign ownership, patents and trademarks 51
  - importance of IPRs to FDI 63
  - innovative capacity 84
  - intellectual property amendments (Section 301) 4
  - international IP policy 4
  - IP position, Seattle 192
  - losses, pirated products 58
  - pharmaceutical exports 84
  - R&D expenditure, pharmaceutical industry 77
  - support for Canada over Bolar exemptions 184
  - trade in IP-related products 54
  - trade retaliation during Uruguay Round 66–9
- United States Trade Representative (USTR) 66
- Uruguay Round
  - establishment of TRIPs agreement 128–9
  - north-south divide 209
  - use of trade retaliation during 66–9
- value
  - in centrally administered reward systems 21–2
  - reputation of brand-name products 36
- Vandoren, Paul 171
- Venezuela, demands on TRIPs 159, 160
- Verband Forschender Arzneimittelhersteller (VFA) 83, 106–7, 208
- Viagra 86
- Watch List 66
- Waxman-Hatch Act (1984) 181–2
- weak IP capability
  - concerns about benefits of TRIPs 157
  - insufficient assistance to countries with 138–40
  - international IP system 49–51, 205
- weak IP protection, FDI 63
- welfare economics model, international IP system 49, 204
- welfare implications, support for IPRs 171
- welfare losses, patent grants 54–5
- WHO EDL list, exclusion from patentability 164
- Wieczorek-Zeul, Heidemarie 173–4
- World Intellectual Property Organization (WIPO) 6–7, 161
- World Trade Organization (WTO), inclusion of IPRs under 4
- Yage 162
- Zeneca 81, 88, 92, 176
- Zocor 86